# Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

> **NCT03944772** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 247 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Osimertinib
- **DRUG:** Savolitinib
- **DRUG:** Gefitinib
- **DRUG:** Necitumumab
- **DRUG:** Durvalumab
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed
- **DRUG:** Alectinib
- **DRUG:** Selpercatinib
- **DRUG:** Selumetinib
- **DRUG:** Etoposide
- **DRUG:** Cisplatin
- **DRUG:** Datopotamab deruxtecan

## Key facts

- **NCT ID:** NCT03944772
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-06-25
- **Primary completion:** 2025-05-06
- **Final completion:** 2025-05-06
- **Target enrollment:** 247 (ACTUAL)
- **Last updated:** 2025-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03944772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03944772, "Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03944772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*